The Technical Analyst
Sunshine Biopharma, Inc. [SBFM]
Exchange: PNK Industry: Drug Manufacturers
Sunshine Biopharma, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.30% $0.840
America/New_York / 3 mai 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 0.835 mill |
| EPS: | -19.00 |
| P/E: | -0.0400 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 0.995 mill |
| Avg Daily Volume: | 1.964 mill |
| RATING 2024-05-03 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Sell | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.0400 | sector: PE -11.58 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -0.0400 | industry: PE -6.21 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ -1.006 - 2.69 ( +/- 219.76%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-04 | Slilaty Steve N. | Buy | 100 000 | Series B Preferred Stock |
| 2024-02-08 | Slilaty Steve N. | Buy | 20 000 | Series B Preferred Stock |
| 2024-01-26 | Beaudoin Marc | Buy | 0 | |
| 2022-11-30 | Sebaaly Camille | Buy | 30 000 | Common Stock |
| 2022-10-20 | Chamoun Malek | Sell | 0 | Common Stock, par value $0.001 per share |
| INSIDER POWER |
|---|
| 100.00 |
| Last 67 transactions |
| Buy: 1 074 426 098 | Sell: 315 420 609 |
Forecast:
16:00 - $0.840
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.840
Forecast 2: 16:00 - $0.840
Forecast 3: 16:00 - $0.840
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.840 (0.30% ) |
| Volume | 4.90 mill |
| Avg. Vol. | 1.964 mill |
| % of Avg. Vol | 249.58 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For SBFM
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
SBFM
Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound. It also offers Essential 9, a nutritional supplement tablet; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements. The company has a license agreement with the University of Georgia to advance the development of its anti-coronavirus lead compound, SBFM-PL4. Sunshine Biopharma, Inc. is headquartered in Pointe-Claire, Canada.
Latest Press Releases
2024-04-19 08:00:00 - Press Release
Sunshine Biopharma's Nora Pharma Receives Health Canada Approval For Niopeg(r), A Biosimilar Of Neulasta(r)
New york, ny / accesswire / april 19, 2024 / sunshine biopharma inc. (nasdaq:sbfm), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals, is happy to announce that its wholly owned generic pharmaceutical subsidiary, nora pharma, has received approval for its first biosimilar product. nora pharma has received approval from health canada for the commercialization of niopeg® (a pegylated form of filgrastim) in canada.
2024-04-12 09:00:00 - Press Release
Sunshine Biopharma Announces Reverse Stock Split
New york, ny / accesswire / april 12, 2024 / sunshine biopharma, inc. (nasdaq:sbfm) (the "company" or "sunshine biopharma"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals, announced today a one for one hundred reverse split of its common stock, effective at market open on april 17, 2024. the reverse stock split was undertaken to regain compliance with nasdaq's minimum bid price requirement for continued listing.
2024-04-01 08:00:00 - Press Release
Sunshine Biopharma Reports Operating Results For The Fiscal Year Ended December 31, 2023
Sales grew at an average rate of 14% per quarter during the year new york, ny / accesswire / april 1, 2024 / sunshine biopharma inc. (nasdaq:sbfm) (the "company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has filed its 2023 financial results on form 10-k on thursday march 28, 2024. the following are highlights of the report: sales in 2023 grew to a total of $24,092,787, primarily as a result of a full year of revenues generated by the acquisition of nora pharma in october 2022.
2024-02-15 09:15:00 - Press Release
Sunshine Biopharma, Inc. Announces Closing Of $10.0 Million Underwritten Public Offering
New york, ny / accesswire / february 15, 2024 / sunshine biopharma, inc. (nasdaq:sbfm) (the "company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals, today announced the closing of a firm commitment underwritten public offering with gross proceeds to the company of approximately $10.0 million, before deducting underwriting discounts and other estimated expenses payable by the company. the offering consisted of 71,428,571 units, consisting of (a) 26,428,571 common units, with each common unit consisting of one share of our common stock, $0.001 par value per share, one-tenth (1/10) of a series a warrant to purchase one share of common stock ("series a warrant") and two-tenths (2/10) of a series b warrant to purchase one share of common stock ("series b warrant"), and (b) 45,000,000 pre-funded units, with each pre-funded unit consisting of one pre-funded warrant to purchase one share of common stock, one-tenth of a series a warrant and two-tenths of a series b warrant.
2024-02-13 09:00:00 - Press Release
Sunshine Biopharma, Inc. Announces Pricing Of $10.0 Million Underwritten Public Offering
New york, ny / accesswire / february 13, 2024 / sunshine biopharma, inc. (nasdaq:sbfm) (the "company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals, today announced the pricing of a firm commitment underwritten public offering with gross proceeds to the company expected to be approximately $10.0 million, before deducting underwriting fees and other estimated offering expenses payable by the company. the offering consists of 71,428,571 units, each consisting of one (1) share of common stock or pre-funded warrant to purchase one share of common stock and 0.1 series a warrants to purchase one (1) share of common stock per warrant, and 0...
Latest News
2024-03-04 09:18:35 - InvestorPlace
Why Is Sunshine Biopharma (SBFM) Stock Down 17% Today?
Sunshine Biopharma (NASDAQ: SBFM ) stock is falling on Monday after the pharmaceutical company received a delisting notice from the Nasdaq Exchange. That delisting notice notes that shares of SBFM stock have been trading for less than the $1 minimum bid price for too long.
2023-05-12 09:50:21 - InvestorPlace
SBFM Stock Alert: Why Sunshine Biopharma Is Down 28% Today
Sunshine Biopharma (NASDAQ: SBFM ) stock is falling on Friday after the pharmaceutical company revealed details of a private offering for its shares. Sunshine Biopharma has agreed to sell 5,952,381 units and pre-funded units at a purchase price of 84 cents per unit to a single healthcare-focused institutional investor.
2023-05-12 06:00:00 - PennyStocks
How to Use Social Media to Make Money Trading Penny Stocks
Use these tips to utilize social media for trading penny stocks The post How to Use Social Media to Make Money Trading Penny Stocks appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2023-05-11 14:05:21 - InvestorPlace
SBFM Stock Alert: Why Sunshine Biopharma Is Up 80% Today
Canadian biotech company Sunshine Biopharma (NASDAQ: SBFM ) is among the leaders in today's rather volatile session. Currently, shares of SBFM stock are up more than 60% after the company announced what appears to be incredible earnings.
2022-12-05 17:46:55 - GuruFocus
4 Stocks Meeting GuruFocus' Value Screens in December
As investors prepare for the holiday season, GuruFocus' value screeners identified several stocks that meet screening criteria based on key principles taught by Benjamin Graham, Peter Lynch and Berkshire Hathaway Inc. ( BRK.A , Financial)( BRK.B , Financial) co-managers Warren Buffett (Trades, Portfolio) and Charlie Munger (Trades, Portfolio). Four stocks that meet such criteria are Sunshine Biopharma Inc. ( SBFM , Financial), Regional Management Corp. ( RM , Financial), West Fraser Timber Co. Ltd.
2022-06-07 14:54:28 - PennyStocks
10 Top Penny Stocks To Buy In June According To These Insiders Part 1
Insiders are buying these penny stocks. The post 10 Top Penny Stocks To Buy In June According To These Insiders Part 1 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-05-09 11:03:31 - GuruFocus
Sunshine Biopharma: An Opportunity Knocking?
Investors with a very high appetite for risk and seeking ultra-high-growth stocks can find potential opportunities within the pharma and biotech domain. Investing in development-stage biopharma companies is a typical high-risk, high-return bet that can end up providing multi-bagger returns if the company's research is successful.
2022-04-26 08:13:09 - InvestorPlace
Multiple Promising Treatments Accentuate the Bull Case for Sunshine Biopharma
SBFM stock is trading at a surprisingly low price, considering Sunshine Biopharma's demonstrably positive clinical results. The post Multiple Promising Treatments Accentuate the Bull Case for Sunshine Biopharma appeared first on InvestorPlace.
2022-04-25 13:37:27 - InvestorPlace
Why Is Sunshine Biopharma (SBFM) Stock Up Today?
Today, investors in Sunshine Biopharma and SBFM stock are getting a huge boost from news that the company filed a patent for a key drug. The post Why Is Sunshine Biopharma (SBFM) Stock Up Today?
2022-04-25 10:57:04 - Benzinga
Why Sunshine Biopharma Stock Is Surging
Sunshine Biopharma Inc (NASDAQ: SBFM) shares are trading higher Monday after the company announced it filed a United States provisional patent application covering the recently communicated mRNA molecules found in pre-clinical trials to be effective at destroying cancer cells grown in.